DIA 2017 Annual Meeting

Component Type: Session
Level: Intermediate
CE: CME 1.25; IACET 1.25; RN 1.25

ue to the increased miniaturization of sensors and circuitry, the health and wellness industry is seeing rapid proliferation in the number and diversity of wearables and sensors to provide personal wellness applications. This provides opportunity to collect greater and richer data during clinical trials and post-marketing studies, and also to develop beyond-the-pill strategies to support the launch or marketing of products. This session explores the implementation of wearables and sensors within clinical trials and mHealth programs. Reporting work of the C-PATH ePRO Consortium, we identify suitable evidence that could be considered to support the selection of wearable devices and the validity of endpoints derived from wearables data in clinical trials. We explore practical considerations for wearable and sensor use in beyond-the-pill mHealth programs. Finally, we examine the experience of one pharmaceutical company in transitioning wearables from pilot evaluations to implementation in trials and mHealth programs. Join Study Endpoints Community for a follow up Round Table discussion at 10:30am Tuesday June 20th in the Community Corner.

Learning Objectives

Describe factors influencing wearable device selection and identify possible evidence needed to support their use to provide trial endpoint data; Identify practical considerations for wearable device use within mHealth programs; Identify how pharma is leveraging wearables from pilot studies to implementation in trials and mHealth programs.

Chair

Bill Byrom, PhD

Speaker

Selection of Wearable Devices and Validation of Health Outcome Assessments Derived from Wearables Data
Bill Byrom, PhD

Transitioning Wearables From Pilot Evaluations to Trials and mHealth Programs
Daragh Ryan

Challenges of Using Consumer Wearables in Beyond the Pill Programs: A Pharma and Patient Perspective
Chris Watson, PhD